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t the end of 2005, about 40 
million people worldwide 
were living with HIV/AIDS, 
most of them adults and 95 percent of 
them living in developing countries. 
Although vigorous prevention 
programs are under way in many 
countries, about 3 million people still 
died from AIDS in 2005 and more 
than 13,000 people became infected 
with HIV every day [1]. Hence there 
is an urgent need for stronger and 
more effective HIV prevention. New 
technologies are required to augment 
existing prevention methods. An HIV 
vaccine could make an enormous 
difference in the effort to reverse 
the pandemic, thereby saving tens of 
millions of lives.
    Vaccines have been highly cost-
effective in ﬁ  ghting other infectious 
diseases such as polio, smallpox, 
hepatitis B, yellow fever, and a range 
of childhood illnesses. A safe, effective, 
and accessible preventive HIV vaccine 
would be a hugely valuable addition 
to the existing array of prevention 
measures. In a number of modeling 
exercises, analysts have shown that 
even a partially effective vaccine 
could decisively lower the rate of new 
infections, averting millions of new 
infections each year [2–4].
    In the global effort to develop an 
HIV vaccine, more than 30 vaccine 
candidates are currently in trials in 19 
developed and developing countries 
[5]. Among these, a large-scale phase 
III trial is under way in Thailand, and a 
major phase IIb trial involving several 
thousand volunteers is ongoing in 
Latin America, the Caribbean, Europe, 
and North America to obtain proof 
of concept for a vaccine built on an 
adenovirus vector platform [6]. The 
results of these trials over the next few 
years will help us set a more deﬁ  nitive 
timeline for the eventual launch and 
introduction of a vaccine.
    Why Estimates of Demand Matter
    For a vaccine to make a difference in 
halting the AIDS pandemic, it needs 
to be widely available and accessible, 
and must be taken up. The vaccine 
must be demanded by individuals 
and government authorities. Reliable 
estimates of demand for an HIV 
vaccine would help in achieving 
several policy and advocacy objectives 
related to this goal, including: (1) 
persuading governments and industry 
to invest more in research and product 
development; (2) convincing donors 
to ﬁ  nance vaccine purchases, in 
advance or at the time of uptake, given 
the limited ability of governments 
and individuals in poor developing 
countries to pay for a vaccine; (3) 
helping industry to determine the 
scale of manufacturing facilities to 
build to ensure adequate production 
capacity; (4) guiding research 
portfolio management decisions by 
highlighting how vaccine characteristics 
may affect demand; and (5) guiding 
governments in planning their HIV 
vaccination programs, including 
developing information campaigns and 
strengthening vaccine delivery systems.
    A successful HIV vaccine is likely 
to have characteristics that make 
estimating demand especially 
challenging. Unlike most existing 
vaccines that are aimed at children, 
an HIV vaccine will probably be 
recommended for adolescents 
and adults. From a public health 
perspective, an HIV vaccine is likely 
to have the largest epidemiological 
impact when targeted at groups 
with high risk of infection, such as 
commercial sex workers (CSWs) and 
injecting drug users (IDUs). However, 
little is known about the uptake of 
vaccines and other health services by 
adults and marginalized social groups 
in developing countries. The ﬁ  rst 
generation of licensed HIV vaccines 
may also be only partially effective in 
protecting against infection and at the 
same time very expensive, which could 
reduce the vaccine’s acceptability to 
both governments and individuals. 
Furthermore, the stigma associated 
with HIV/AIDS, if not adequately 
addressed, may lower demand for a 
vaccine.
    For these reasons, ascertaining the 
private and public demand for an HIV 
vaccine is important—but until now, 
such estimates have been incomplete 
and based on product proﬁ  les (efﬁ  cacy, 
mode of action, duration) that differ 
substantially from the proﬁ  les of the 
HIV vaccines currently in the research 
and development pipeline.
    It is therefore critical that a renewed 
effort be made to develop and 
implement models for HIV vaccine 
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demand that capture the key drivers 
of expected demand; are based on the 
latest and best scientiﬁ  c knowledge; 
and are ﬂ  exible and can be updated 
periodically as the vaccine ﬁ  eld 
advances in the coming years.
    What Do We Know about HIV 
Vaccine Demand?
    To assess the state of HIV vaccine 
demand analysis and the need for 
further work in these areas, a team 
from the International AIDS Vaccine 
Initiative (IAVI) reviewed the existing 
scientiﬁ  c literature, including 18 
previous studies (see bibliography 
available at http:⁄⁄www.iavi.org/
annotated). The results from these 
studies were synthesized [7].
      Global estimates.   At the global 
level, three estimates of demand for 
an HIV vaccine have been made to 
date. The ﬁ  rst focuses on the number 
of vaccination courses required by 
developing countries for national 
HIV vaccination programs in the ﬁ  rst 
ﬁ  ve years after vaccine launch [8]. 
(A “course” refers to two or more 
vaccinations administered to the same 
individual several months apart, as 
is done for many vaccines currently 
in use.)  The second used marginal 
beneﬁ  t and opportunity cost analysis 
to estimate the volume of vaccine 
purchases globally [9]. The most 
recent study is based on public health 
needs and probable vaccine uptake in 
developed and developing countries 
[10].
    Results of these studies are presented 
in Figure 1. The three studies converge 
on an estimated demand for the 
developing world of several hundred 
million vaccine courses in the early 
“catch-up” years when large numbers 
of adults are being vaccinated. Because 
of constraints on accessibility and 
acceptability, one study argues that 
effective uptake of an HIV vaccine 
would only be 49 million courses for a 
low- to moderate-efﬁ  cacy vaccine, but 
would reach 260 million courses for a 
high-efﬁ  cacy product in the ﬁ  rst ﬁ  ve 
years after its introduction.
      Country-level estimates.   Four 
studies have looked at public sector 
demand for an HIV vaccine at country 
level for Thailand, Brazil, Southern 
Africa, and Southern India [11–14]. 
The population groups assumed to 
be vaccinated in each study varied 
in response to local political and 
epidemiological factors. In the 
Southern India, Southern Africa, 
and Thailand analyses, groups were 
prioritized for vaccination on the basis 
of cost-effectiveness. Relative costs 
were adjusted to reﬂ  ect the difﬁ  culty 
of reaching those population groups. 
In calculating the number of infections 
averted, the Thailand and Brazil studies 
considered whether an HIV vaccine 
would complement or substitute for 
existing HIV prevention methods 
such as condoms. The Brazil study did 
not use cost-effectiveness because the 
authors believed that the prevailing 
national political outlook on AIDS and 
health would require the government 
to vaccinate every individual, regardless 
of risk status.
    The studies made different 
assumptions about the share of 
population groups vaccinated—partial 
or complete coverage—at the time of 
product introduction. The study of 
Southern Africa argues for targeting 
high-risk groups and for providing 
vaccination to individuals after they 
receive voluntary counseling and 
testing. The Southern India study 
developed vaccine delivery scenarios 
for each population group. The 
Thailand study proposes that vaccines 
be allocated strictly on the basis of 
relative cost-effectiveness across groups, 
for given levels of government budget 
resources.
    A simple vaccine product proﬁ  le 
was used in all four studies, typically a 
single dose with 100 percent efﬁ  cacy. 
For Southern Africa and Southern 
India, it was assumed that the vaccine 
would only offer protection from HIV 
infection for ﬁ  ve years, while the Brazil 
and Thailand studies assumed lifetime 
protection. A series of prices from 
US$1 to US$10 a dose was considered, 
except in Thailand where the price 
ranged up to US$28 per dose.
    The potential demand was calculated 
by multiplying population size by the 
estimated coverage rate (Figure 2). The 
required budget was then estimated 
DOI: 10.1371/journal.pmed.0030398.g001
  Figure 1.   Results from Global Public Sector Demand Studies   
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by multiplying price by the number of 
doses.
    The four studies suggest that the 
number of doses of HIV vaccines 
needed in the initial phase could be 
large if broad targeting is followed—
over 121 million doses in Brazil and 
195 million doses in Southern India. 
If a narrower targeting strategy to 
reach only high-risk populations were 
followed, however, the number of 
doses needed would be signiﬁ  cantly 
smaller—9.1 million doses in Brazil 
for those at greatest risk, 9.6 million 
doses in Southern India when focusing 
exclusively on high-risk individuals 
and women receiving antenatal care 
services, and 1.3 million doses for 15-
year-old school students in Southern 
Africa. The Thai study argues that 
5.9 million doses would cover priority 
groups in the country, with an 
additional 1.3 million doses needed 
annually to maintain coverage.
      Private demand.   Studies have been 
conducted in four countries—Kenya, 
Mexico, Thailand, and Uganda—
among samples of the adult population, 
such as patrons of shopping centers, 
households in various communities, 
students, and adolescents [15–19]. One 
study included respondents at high risk 
of infection: CSWs and IDUs [15].
    Efﬁ  cacy level, number of doses, 
duration, and price were the most 
commonly used vaccine characteristics. 
Although most studies explored 
demand for a partial-efﬁ  cacy vaccine, 
the Thailand study was the ﬁ  rst to 
develop a tool to explain this concept 
to respondents and check their 
understanding [16].
    Figure 3 reports the proportion of 
individuals who expressed willingness 
to pay (WTP) for an HIV vaccine. 
Even though less than 100 percent 
of population groups studied might 
beneﬁ  t from being vaccinated, the 
reported level of demand is still high, 
even when individuals were asked to 
pay out of pocket. In Uganda, more 
than three-quarters of the general 
population said they would purchase a 
vaccine at about US$3 a dose, while in 
Thailand more than three-quarters of 
CSWs and IDUs would buy a vaccine at 
US$25 a dose.
    When asked about an HIV vaccine 
offered free of charge, the proportion 
of respondents who expressed 
willingness to be vaccinated (WTV) 
increased to 78 percent and 94 percent 
of the general population in Thailand 
and Uganda, respectively, and 97 
percent of CSWs and 95 percent of 
IDUs in Thailand (Figure 3). In Kenya, 
where vaccine price was not explored, 
WTV was about 65 percent for a 50 
percent effective vaccine and slightly 
higher for a 100 percent effective 
vaccine.
    Regression analysis found that the 
general population in the two East 
African countries and respondents at 
high risk for HIV infection in Thailand 
showed indifference to vaccine efﬁ  cacy 
[15–18]. In contrast, the sample from 
the general population in Thailand, 
facing a longstanding but less severe 
epidemic, showed a preference for a 
higher-efﬁ  cacy vaccine at any given 
price [16]. This conﬁ  rms the role of 
perceived HIV risk in determining the 
demand for an HIV vaccine.
    The study in Thailand explored 
the comparative proportions of 
respondents in each of three groups—
the general population, CSWs, and 
IDUs—willing to pay for an HIV 
vaccine at prices from US$12.50 to 
US$500 [15]. CSWs were the most 
likely to pay at a given price, followed 
by IDUs and the general population. 
Willingness to pay fell for all groups as 
price rose, dropping below 25 percent 
at the US$500 level for the general 
population even for a 95 percent 
effective vaccine.
    Two of ﬁ  ve studies explored the 
effect of vaccine price and found 
that higher prices reduce demand 
[16,18]. They also suggest that greater 
understanding of vaccine efﬁ  cacy 
can raise demand and willingness to 
pay for a vaccine. This is important 
for the design of future promotional 
campaigns to persuade people to 
participate in HIV vaccination.
      Lessons for policy makers.   The 
existing literature on demand for HIV 
vaccines points to several important 
lessons for policy makers. First, with a 
potential demand of several hundred 
million doses in developing countries 
during an initial period, HIV vaccine 
manufacturers should be persuaded 
that this represents an attractive market 
in volume terms, with the price per 
dose as the main uncertainty. To 
address this latter issue, developed 
country governments could guarantee 
a reasonable price (e.g., US$5–US$10 
DOI: 10.1371/journal.pmed.0030398.g002 
  Figure 2.   Number of Doses of HIV Vaccine Required by the Public Sector (in Millions, Unless 
Otherwise Indicated), Four Country Studies   
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per dose) for an HIV vaccine that 
met certain technical performance 
standards. A pilot scheme along these 
lines is being recommended to the 
G8 governments under the current 
advance market commitment proposal 
for new vaccines (http:⁄⁄www.cgdev.
org/section/initiatives⁄_active/
vaccinedevelopment).  
    Second, since the vaccine delivery 
and targeting strategies followed by 
developing countries will signiﬁ  cantly 
affect the size of global demand, it is 
imperative that market forecasts for an 
HIV vaccine take into account these 
country-speciﬁ  c targeting preferences. 
These preferences are especially 
important in countries with large 
populations such as India, China, South 
Africa, Ethiopia, and Nigeria, since 
demand from these countries will drive 
the global demand numbers.
    A third lesson for policy makers is 
that with private demand for an HIV 
vaccine among low-risk groups likely 
to be substantially affected by price, 
governments and donors will need to 
design polices to reduce the price of 
the vaccine to consumers, especially for 
low-income households. Direct public 
sector subsidies backed up by donor 
commitments and publicly ﬁ  nanced 
health insurance schemes are two 
approaches that could help to make 
a vaccine affordable in these settings, 
thus transforming public health need 
into actual demand and uptake.  
    Why Do We Need Better Estimates, 
and How Should They Be Done?
    While suggestive and helpful, existing 
studies of global, regional, and 
country-level demand for a future HIV 
vaccine are inadequate and need to be 
signiﬁ  cantly improved. Why?
    First, they assume optimistically 
that all countries would adopt the 
vaccine in year 1, without staggering 
or sequencing introduction. 
Although many national leaders and 
international partners will no doubt 
endeavor to see that countries adopt 
an effective HIV vaccine as quickly as 
possible, past experience with other 
vaccines has shown that some countries 
are fast adopters and others are slower 
[20,21]. This needs to be taken into 
account in future uptake scenarios to 
make them more realistic.
    The starting date for an AIDS 
vaccination program, the speed with 
which the vaccine will be taken up, 
the population targeting and vaccine 
delivery strategies, and the maximum 
achievable coverage level will vary from 
country to country, driven by a range 
of factors that need to be carefully 
explored and incorporated into 
demand scenarios. These include: (1) 
knowledge of HIV/AIDS; (2) awareness 
of the vaccine and its potential beneﬁ  ts; 
(3) the strength and reach of existing 
national and local vaccination and 
health programs; (4) human resources 
and management capacity; (5) 
political leadership and community 
mobilization capacity; and (6) 
cultural variables related to the stigma 
surrounding HIV/AIDS and AIDS 
prevention services generally. Data are 
already available for a number of these 
factors, and others can be estimated 
using proxy variables for which data 
also exist. In some instances, additional 
data will need to be collected.
    Second, a number of the existing 
HIV vaccine demand studies do 
not rigorously examine the effects 
of vaccine price on government 
or individual private decisions. 
Furthermore, in cases where price has 
been considered, the price levels tested 
are not consistent across population 
groups and countries in a manner that 
allows for straightforward international 
comparisons. In the future, it would be 
useful to undertake additional analysis 
of public and private willingness to 
pay for an HIV vaccine, using agreed-
upon standardized price levels that are 
consistent across countries with similar 
per capita incomes.
    While public sector demand is 
extremely important to ascertain, given 
the dominant role of governments in 
sponsoring and paying for vaccines 
in both developed and developing 
countries, private demand and price 
sensitivity are also important, especially 
in middle-income countries where the 
private sector is often highly dynamic in 
the health-care ﬁ  eld. In these settings, 
studies of private willingness to pay 
can generate important insights into 
strategies for government subsidies 
that would be equitable and help to 
augment overall vaccine uptake.
    Third and ﬁ  nally, the existing 
vaccine demand studies use vaccine 
characteristics that are internally 
inconsistent and do not reﬂ  ect current 
scientiﬁ  c opinion. Current opinion 
suggests that the ﬁ  rst HIV vaccines 
licensed for use may be only partially 
effective and may act in three ways: 
(1) by preventing some but not all 
vaccinated persons from becoming 
infected (“partial efﬁ  cacy” or “reduced 
susceptibility” to HIV infection); (2) 
by lowering a vaccinated individual’s 
infectiousness (and thus his or her 
ability to infect others); and (3) 
by reducing the rate at which an 
individual would progress to AIDS 
disease if infected with HIV.
    A standardized and up-to-date proﬁ  le 
of these hypothetical ﬁ  rst-generation 
HIV vaccines, based on the latest 
scientiﬁ  c knowledge, would help to 
generate the most policy-relevant and 
comparable results from future vaccine 
demand assessments.
  Conclusion
    While we have already gained some 
valuable understanding of public and 
private demand for HIV vaccines from 
existing studies, additional research on 
these topics is needed to strengthen 
ongoing advocacy and planning for 
eventual vaccine introduction. This 
type of demand analysis can also 
beneﬁ  t from parallel efforts to improve 
demand forecasting for other vaccines 
and pharmaceutical products and 
from deeper involvement of modelers, 
DOI: 10.1371/journal.pmed.0030398.g003
  Figure 3.   Reported Willingness to Pay and to Be Vaccinated in Four Countries   
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economists, and policy makers from 
developing countries where the AIDS 
epidemic is most acute.
    IAVI and its partners in HIV 
vaccine development should seize 
this opportunity to mount a focused 
program of policy research into vaccine 
demand, globally and at country level. 
The World Health Organization, the 
Joint United Nations Program on 
HIV/AIDS, the United States National 
Institutes of Health, other national 
medical research institutions, and a 
number of health policy organizations 
all have much to offer to this effort. 
If combined effectively with parallel 
policy analysis on vaccine impact, 
cost-effectiveness, and strategies for 
ﬁ  nancing and delivering an HIV 
vaccine, such additional work on 
vaccine demand could make an 
important contribution to speeding up 
development and access to a vaccine 
that could help to stop the epidemic 
and end AIDS.   
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